middle.news
Amplia Therapeutics Achieves Rare Complete Response in Advanced Pancreatic Cancer Trial
8:43am on Monday 16th of June, 2025 AEST
•
Healthcare
Read Story
Amplia Therapeutics Achieves Rare Complete Response in Advanced Pancreatic Cancer Trial
8:43am on Monday 16th of June, 2025 AEST
Key Points
Pathological complete response (pCR) observed in advanced pancreatic cancer patient
ACCENT trial testing narmafotinib combined with chemotherapy
pCR is exceptionally rare in metastatic pancreatic cancer
Surgical removal showed no live tumor tissue post-treatment
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE